Lys Therapeutics is a biotechnology company pioneering a revolutionary approach to treat patients suffering from neurodegenerative or neurovascular disorders.

Their main asset, LYS241, is a first-in-class monoclonal antibody currently completing its preclinical development. The disruptive approach of Lys Therapeutic’s technology: an exclusive and fully characterized mechanism of action counteracting blood-brain barrier (BBB) dysfunction and associated neuroinflammatory issues leading to neurodegeneration, without the need for the antibody to cross the BBB to act on the CNS, which is a major advantage over most of other competitive approaches.

-–

Lys Therapeutics, in a nutshell:

• Company incorporated in March 2021 with onboard an experienced managerial team as well as two governance committees: 1) an international Scientific Advisory Board composed of key opinion